在西班牙人口中瘤药物遗传特征的多样性
Irene Ferrer Bolufer1, Ximo Galiana Vallés1, Silvia Izquierdo Álvarez2
1Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia.
Pharmacogenetics and genomics
|March 15, 2024
概括
对DPYD基因变异的药物遗传学测试可以预防由胺化疗引起的严重毒性. 本研究详细介绍了西班牙人群中关键DPYD和UGT1A1变异的等位基分布,以指导药物处方.
科学领域:
- 药物基因组学 药物基因组学
- 临床化学 临床化学
- 在瘤学瘤学.
背景情况:
- 已建立的指导方针建议基因型引导的胺剂量,以减轻严重的毒性.
- 基因变异可显著影响药物代谢和患者的治疗结果.
- 了解基分布对于安全有效的抗瘤药物处方至关重要.
研究的目的:
- 描述特定DPYD和UGT1A1变体的等位基分布.
- 提供关键的药物遗传学数据,用于皮里米丁和皮里米丁治疗的管理.
- 评估瓦伦西亚,阿拉贡和西安达卢西亚人群的变异频率.
主要方法:
- 在UGT1A1*28 (rs3064744) 和DPYD变种 (DPYD*2A,c.1679T>G,c.2846A>T,c.1129-5923C>G) 中进行基因造型.
- 分析了一组由5251名接受虹色素和胺酸治疗的患者组成的队列.
- 基于人群的等位基频率的确定.
主要成果:
- 获得了UGT1A1*28和多个DPYD变异的详细等位基分布数据.
- 在一大群代表特定西班牙人口的患者队列中确定了频率.
- 该研究提供了与临床实践相关的变异频率的精确描述.
结论:
- 基因分布数据对于优化以基因型为导向的氨酸和氨酸的剂量至关重要.
- 这些药物遗传信息支持预防严重的药物不良反应.
- 这些发现有助于个性化医学在癌症治疗中的方法.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254


